U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.38%

Investing.com – Mexico stocks were higher after the close on Friday, as gains in the Industrials, Consumer Goods & Services and Consumer Staples sectors led shares higher.

At the close in Mexico, the S&P/BMV IPC rose 0.45%.

The best performers of the session on the S&P/BMV IPC were Controladora Vuela Compania de Aviacion SAB de CV (BMV:VOLARA), which rose 14.84% or 2.21 points to trade at 17.10 at the close. Meanwhile, Industrias Penoles Sab De CV (BMV:PEOLES) added 8.02% or 64.42 points to end at 867.64 and Bolsa Mexicana De Valores SAB De CV (BMV:BOLSAA) was up 7.41% or 2.74 points to 39.72 in late trade.

The worst performers of the session were Grupo Televisa SAB Unit (BMV:TLEVISACPO), which fell 8.76% or 1.00 points to trade at 10.41 at the close. GCC SAB de CV (BMV:GCC) declined 3.97% or 7.65 points to end at 185.00 and Grupo Mexico, S.A.B. De C.V. (BMV:GMEXICOB) was down 2.92% or 4.96 points to 165.06.

Rising stocks outnumbered declining ones on the Mexico Stock Exchange by 143 to 85 and 18 ended unchanged.

Shares in Industrias Penoles Sab De CV (BMV:PEOLES) rose to all time highs; up 8.02% or 64.42 to 867.64.

Gold Futures for February delivery was up 0.10% or 4.15 to $4,368.65 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in February rose 0.95% or 0.53 to hit $56.53 a barrel, while the February Brent oil contract rose 1.14% or 0.68 to trade at $60.50 a barrel.

USD/MXN was up 0.23% to 18.03, while EUR/MXN rose 0.15% to 21.12.

The US Dollar Index Futures was up 0.27% at 98.35.

Investing.com – Canada stocks were higher after the close on Friday, as gains in the IT, Materials and Energy sectors led shares higher.

At the close in Toronto, the S&P/TSX Composite rose 1.00% to hit a new all time high.

The best performers of the session on the S&P/TSX Composite were Celestica Inc. (TSX:CLS), which rose 9.21% or 34.35 points to trade at 407.37 at the close. Meanwhile, Energy Fuels Inc. (TSX:EFR) added 8.10% or 1.56 points to end at 20.82 and NexGen Energy Ltd. (TSX:NXE) was up 7.51% or 0.88 points to 12.59 in late trade.

The worst performers of the session were BlackBerry Ltd (TSX:BB), which fell 14.10% or 0.85 points to trade at 5.18 at the close. Curaleaf Holdings Inc (TSX:CURA) declined 6.12% or 0.27 points to end at 4.14 and West Fraser Timber Co Ltd (TSX:WFG) was down 3.84% or 3.26 points to 81.56.

Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 597 to 305 and 71 ended unchanged.

The S&P/TSX 60 VIX, which measures the implied volatility of S&P/TSX Composite options, was up 3.55% to 12.26.

Gold Futures for February delivery was up 0.10% or 4.40 to $4,368.90 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in February rose 0.95% or 0.53 to hit $56.53 a barrel, while the February Brent oil contract rose 1.14% or 0.68 to trade at $60.50 a barrel.

CAD/USD was unchanged 0.16% to 0.72, while CAD/EUR unchanged 0.07% to 0.62.

The US Dollar Index Futures was up 0.27% at 98.35.

Investing.com -- Cytokinetics Inc (NASDAQ:CYTK) stock rose 3.6% in after-hours trading on Friday following the U.S. Food and Drug Administration’s approval of MYQORZO, the company’s first FDA-approved medicine.

The drug, also known as aficamten, was approved for treating adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. MYQORZO works as an allosteric and reversible inhibitor of cardiac myosin motor activity, addressing the underlying hypercontractility associated with the condition.

"This is a historic moment for our company and for the patients we serve, as we fulfill our promise to translate our science into medicines that may make a meaningful difference in patients’ lives," said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer.

The approval is based on results from the SEQUOIA-HCM clinical trial. According to Martin Maron, Principal Investigator of the trial, "MYQORZO improved exercise capacity and reduced symptoms while also being well-tolerated."

The drug’s prescribing information includes a Boxed WARNING regarding the risk of heart failure, as MYQORZO reduces left ventricular ejection fraction and can cause heart failure due to systolic dysfunction. Echocardiogram assessments are required before and during treatment.

Cytokinetics expects MYQORZO to be available in the U.S. in the second half of January 2026. The company will support patients with a personalized program called MYQORZO & You to help navigate treatment, provide education, and offer insurance benefits support.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com – Colombia stocks were lower after the close on Friday, as losses in the Financials, Investment and Public Services sectors led shares lower.

At the close in Colombia, the COLCAP declined 0.30%.

The best performers of the session on the COLCAP were Grupo Nutresa SA (BVC:NCH), which rose 3.76% or 9,960.00 points to trade at 274,960.00 at the close. Meanwhile, Grupo de Inversiones Suramericana SA Preferred (BVC:SIS_p) added 2.71% or 1,180.00 points to end at 44,680.00 and Organizacion Terpel SA (BVC:TPL) was up 1.85% or 360.00 points to 19,840.00 in late trade.

The worst performers of the session were Grupo Bolivar SA (BVC:SCA), which fell 1.42% or 1,300.00 points to trade at 90,240.00 at the close. Ecopetrol SA (BVC:ECO) declined 0.83% or 15.00 points to end at 1,800.00 and Banco Davivienda Pf (BVC:DVI_p) was down 0.78% or 200.00 points to 25,300.00.

Rising stocks outnumbered declining ones on the Colombia Stock Exchange by 1 to 0.

Shares in Organizacion Terpel SA (BVC:TPL) rose to all time highs; up 1.85% or 360.00 to 19,840.00.

US coffee C for March delivery was down 1.13% or 3.90 to $341.20 . Elsewhere in commodities trading, US cocoa for delivery in March fell 1.42% or 84.00 to hit $5,850.00 , while the February Gold Futures contract rose 0.11% or 4.60 to trade at $4,369.10 a troy ounce.

USD/COP was down 1.42% to 3,809.00, while BRL/COP fell 1.81% to 687.61.

The US Dollar Index Futures was up 0.28% at 98.36.

Investing.com -- The S&P 500 rose Friday as investors continued bullish bets on the AI-linked stocks extending the rebound from a day earlier and pushing the broader tech sector higher.

At 3:23 p.m. ET (20:23 GMT), the Dow Jones Industrial Average rose 222 points, or 0.5%, the S&P 500 index gained 0.9%, and the NASDAQ Composite climbed 1.2%. That said, these benchmarks are still on course for a losing week, with the broad-based S&P 500 and the blue chip Dow Jones Industrial Average down about 0.8% and 1%, respectively. The tech-heavy NASDAQ Composite is also down 0.8% week to date.

 For top stock picks and insights into Wall Street’s biggest firms, subscribe to InvestingPro - get 55% off today.

December inflation print looms large

Sentiment received a boost after a softer-than-expected consumer price index inflation reading for November advanced expectations that the Federal Reserve will cut interest rates further in the coming year.

But analysts warned that the November reading was unlikely to factor into the Fed’s rate outlook, given that it was still affected by some lingering disruptions from a government shutdown in October. 

Goldman Sachs analysts said Thursday’s reading was “unlikely to move the needle” for the Fed, stating that December’s data will be much more significant for policymakers in gauging whether inflation was cooling.

Additionally, Federal Reserve Bank of New York ‍President John ‍Williams said Friday that he ⁠did not ‍see any imminent need to follow last week’s interest rate cut ​with another easing.

In a CNBC interview, the Fed official said ‌he ​did not have a “sense of ⁠urgency” ⁠to lower rates, saying “I think ​the cuts we’ve ⁠made have positioned ⁠us really ‌well” to ‌help get inflation down while helping to support a cooling job market.

Still, Goldman Sachs expects the global equity bull market to broaden further in 2026, with returns spreading beyond U.S. technology stocks as earnings growth continues across regions.

Strategists led by Peter Oppenheimer forecast around 13% price returns for global equities in 2026, rising to about 15% including dividends, largely driven by earnings rather than valuation expansion.

The team argues that, given its macro outlook of continued economic expansion and modest easing by the U.S. Federal Reserve, “it would be unusual to see a significant equity setback/bear market without a recession, even from elevated valuations.”

AI stocks continue rebound, led by Oracle; Nike slumps 

Oracle (NYSE:ORCL) stock rallied Friday, aided by reports that the software company was part of an American consortium that will buy social media giant TikTok’s U.S. operations. Mizuho analysts said the deal could help boost demand for Oracle’s non-artificial intelligence, high-margin cloud business. 

Other AI-linked stocks followed Oracle higher, with CoreWeave Inc (NASDAQ:CRWV) among the biggest gainers as Citi said the stock could double from current levels, while the cloud infrastructure company also announced that it had joined the Department of Energy’s efforts advance U.S. research and innovation. 

FedEx Corporation (NYSE:FDX) stock cut losses as the logistics and delivery giant reported stronger-than-expected fiscal second quarter earnings, but still flagged a highly challenging macro environment. Fedex’s strong earnings and positive guidance was driven chiefly by ongoing cost-cutting measures at the delivery giant. 

Nike (NYSE:NKE) stock slumped after the sportswear giant reported shrinking quarterly margins and a decline in revenue in its Greater China market during the fiscal second quarter, its sixth straight quarterly sales decline in the country.

CEO Elliott Hill said in the company’s post-earnings call that "it’s clear we need to reset our approach to the China marketplace," which ‍accounts for roughly 15% of revenue.

Ambar Warrick contributed to this article

Medtronic plc (MDT) filed a registration statement with the U.S. Securities and Exchange Commission for an initial public offering of its diabetes business, which will operate under the name MiniMed, according to a company statement.

The medical device company plans to separate the diabetes unit through capital markets transactions, with an IPO and subsequent split-off as the preferred path. MiniMed intends to list its common stock on the Nasdaq Global Select Market under the ticker symbol MMED.

The number of shares to be offered and the price range have not been determined. The IPO is expected to begin after the SEC completes its review process, subject to market and other conditions.

Goldman Sachs & Co. LLC, BofA Securities, Citigroup and Morgan Stanley will serve as active bookrunners for the offering. Additional joint bookrunning managers include Barclays Capital Inc., Deutsche Bank Securities Inc., Mizuho Securities USA LLC, Wells Fargo Securities, Evercore ISI and Piper Sandler & Co. BTIG, LLC and William Blair & Company, L.L.C. will act as co-managers.

The registration statement has been filed but has not yet become effective. The securities cannot be sold until the registration statement becomes effective.

Medtronic’s diabetes business develops continuous glucose monitoring systems, insulin pumps and diabetes management technology. The Ireland-based company employs more than 95,000 people across 150 countries and manufactures medical devices including cardiac devices, surgical robotics and patient monitoring systems.